Cactus Acquisition 1 Stock Price, News & Analysis

Cactus Acquisition Corp. 1 Limited (associated with the trading symbol CCTSW) is a blank check company. According to the company, it was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. As a blank check or special purpose acquisition company (SPAC), it was created to identify and combine with an operating business rather than to conduct traditional stand‑alone operations.

The company has stated that it has been focusing its search on Israel-related technology-based healthcare companies as potential business combination targets. This focus defines the type of operating businesses it seeks to merge with, although the description does not specify particular products, services, or sub‑sectors within healthcare or technology.

Cactus Acquisition Corp. 1 Limited has securities listed on Nasdaq under symbols that include CCTS, CCTSU and CCTSW, reflecting its ordinary shares, units, and warrants as referenced in public disclosures. Its jurisdiction of incorporation is the Cayman Islands, and it has principal executive offices in Cranbury, New Jersey, as indicated in its SEC filings.

As a SPAC, Cactus Acquisition Corp. 1 Limited’s business model centers on raising capital through the public markets and then seeking a suitable business combination. Until such a transaction is completed, its activities are generally limited to organizational matters, regulatory compliance, and evaluating potential targets, as described in its public statements.

According to a company news release, Cactus Acquisition Corp. 1 Limited filed its annual report on Form 10‑K for the year ended December 31, 2021 with the Securities and Exchange Commission. The company notes that copies of this annual report and other filings are available through the SEC’s EDGAR system.

Business focus and structure

The company describes its purpose as effecting a business combination transaction with one or more businesses. The forms of combination it cites include merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. This language reflects the range of transaction structures that SPACs commonly use, and it indicates that Cactus Acquisition Corp. 1 Limited is not limited to a single transaction format.

The company’s stated focus on Israel-related technology-based healthcare companies indicates a sector and geographic orientation for its search efforts, but it does not provide further detail on specific therapeutic areas, technologies, or business models within that space. The available information does not identify a completed business combination, so the description remains centered on its role as a blank check company seeking a target.

Regulatory and corporate information

Public disclosures show that Cactus Acquisition Corp. 1 Limited is subject to SEC reporting requirements, including the filing of annual reports on Form 10‑K and current reports on Form 8‑K. An 8‑K filing identifies the company as incorporated in the Cayman Islands and provides its Commission File Number. The same filing lists its principal executive offices in Cranbury, New Jersey.

In a Form 8‑K, the company reported a change in the composition of its Board of Directors. The filing states that on June 18, 2025, an independent director, Jeff LeBlanc, notified the company that he resigned from the Board, effective immediately. The company disclosed that his resignation was for personal reasons and did not result from any disagreement with the company on matters relating to operations, policies, practices, accounting principles or practices, financial statement disclosure, or internal controls.

Warrants and listed securities

SEC filing information references Cactus Acquisition Corp. 1 Limited’s class ordinary shares with a par value of 0.0001 per share and redeemable warrants, with each warrant exercisable for one class ordinary share at an exercise price of 11.50. The symbol CCTSW is associated with the company’s warrants. These details indicate that investors can trade both equity and warrant instruments linked to Cactus Acquisition Corp. 1 Limited on the Nasdaq market.

The company’s units and warrants are typical of SPAC capital structures, in which public investors receive shares and warrants that may become exercisable upon completion of a qualifying business combination. The information provided, however, does not describe any completed transaction or the subsequent status of the warrants beyond their basic terms.

Company status and available information

The available news and SEC filing excerpts confirm that Cactus Acquisition Corp. 1 Limited has filed required reports, including a Form 10‑K for the year ended December 31, 2021 and a Form 8‑K regarding a director’s resignation. There is no explicit mention in the provided materials of a completed merger, liquidation, delisting, or similar status change, and no deregistration or delisting forms are cited in the input data.

Investors and researchers looking at CCTSW are examining the warrants associated with this blank check company and may review the company’s SEC filings for details on its structure, governance, and progress in identifying or pursuing a business combination.

Key characteristics of Cactus Acquisition Corp. 1 Limited

• Blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
• Stated focus on Israel-related technology-based healthcare companies as potential business combination targets.
• Incorporated in the Cayman Islands, with principal executive offices in Cranbury, New Jersey as disclosed in SEC filings.
• Securities listed on Nasdaq, including ordinary shares and redeemable warrants, with the warrants associated with the symbol CCTSW.
• Subject to SEC reporting requirements, including annual reports on Form 10‑K and current reports on Form 8‑K.
• Reported a Board resignation of an independent director for personal reasons, with no disagreement on company matters cited in the filing.